 |
|
|
|
 |
|
|
| Article 1 to 10 out of 38 concerning Genentech, Inc.
|
-
Genentech invests in BioInvent to develop cardiovascular antibodies
(04/08/2008)
BioInvent has entered a strategic partnership with Genentech. Genentech has invested in BioInvent's proprietary antibody for the potential treatment of cardiovascular diseases, and will help co-develop and commercialise the product.BioInvent's ...
-
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
(03/11/2008)
Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer
Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) ...
-
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel
(08/28/2007)
Genentech, Inc. announced that the company resubmitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for AvastinŽ (bevacizumab), in combination with paclitaxel chemotherapy, for patients who have ...
-
Dako enters new collaboration on targeted therapies for non-small cell lung cancer
(08/22/2007)
Dako has entered into collaboration with Genentech, OSI and Roche for the clinical development and application for a Premarket Approval Supplement (sPMA) and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the ...
-
Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
(04/20/2007)
Lexicon Genetics Incorporated announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, ...
-
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility
(03/29/2007)
Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Singapore's efforts to grow its biologics manufacturing sector received a significant boost when the Singapore Economic Development Board (EDB) announced that Genentech, Inc. has decided to establish a commercial scale microbial-based biologics ...
-
Genentech Announces Positive Results from Phase IV Study of Raptiva in Patients With Psoriasis
(02/06/2007)
Genentech, Inc. announced results from a Phase IV study of RaptivaŽ (efalizumab) that showed statistically significant improvement in patients with chronic moderate-to-severe plaque psoriasis involving the hands and feet. The 12-week study is the ...
-
Amphora Sells Oncology Program to Genentech
(01/12/2007)
Amphora Discovery Corporation announced that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology ...
-
Genentech Announces Positive Results from a Randomized Phase II Study of Pertuzumab
(01/08/2007)
Genentech, Inc. announced encouraging results from a randomized Phase II study comparing pertuzumab plus gemcitabine to gemcitabine alone in women with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Data from the study ...
-
Roche identifies disease areas addressed in collaboration with Genmab
(12/11/2006)
Genmab A/S announced that the company's partner Roche has named the disease areas for the antibody programs developed with Genmab. These include inflammation, oncology, respiratory and vascular diseases. The antibodies are primarily at the ...
|
|
|
|
|
Top
